Ginkgo Bioworks Holdings, Inc. DNA

Full chart Compare
Set alert

Price alert · DNA

All alert types
10.76 USD +0.91 (+9.24%)

At closeNov 3, 2026, 4:43 PM EST

10.76 0.00 -0.02%

After hours · Nov 3, 4:43 PM ET

10.03 Day range 10.80
5.37 52-week range 18.22
YTD
+29.48%
1 year
-15.87%
Market cap
724.58M
Revenue (ttm)
132.42M
Profit margin
-219.61%
EPS (ttm)
-5.06
Shares out
55.38M
Forward P/E
-5.17
YTD return
+29.48%
1-year return
-15.87%
Volume
2.52M
Avg volume
2.26M
Open
10.06
Previous close
9.85
Day's range
10.03 – 10.80
52-week range
5.37 – 18.22
Beta
1.79
Price target
7.00 (-34.9%)
Earnings date
Nov 5, 2026

15m -1.44 (-11.94%)

101214Oct 28Oct 29Oct 30Nov 2Nov 310.62

Key statistics

Enterprise value
933.60M
PEG ratio
0.00
Price / sales
7.62
Price / book
2.27
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-48.50%
Free cash flow
-72.40M
Total cash
302.16M
Total debt
404.11M
Return on equity
-59.94%
Short % of float
13.36%
50-day average
8.08
200-day average
8.32

Financials — quick view

All financials
DNA Revenue — quarterly 20.16M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNA Net income — quarterly -46.71M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNA EPS — quarterly -0.75
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.58———
Aug 5, 2026Jun 30, 2026-0.895-0.75+0.15+16.20%
May 7, 2026Mar 31, 2026-1.21-1.39-0.18-14.77%
Feb 26, 2026Dec 31, 2025-1.80-1.42+0.38+21.11%
Nov 6, 2025Sep 30, 2025-1.24-1.45-0.21-16.94%
Aug 7, 2025Jun 30, 2025-1.44-1.10+0.34+23.61%

Upgrades / downgrades

DNA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 4, 2026BTIGreitSellSell
Aug 7, 2026TD CowendownBuyHold
Mar 12, 2026BTIGmainSellSell
Jan 8, 2026TD CowenmainBuyBuy
Aug 25, 2025BTIGmainSellSell
Sep 20, 2024TD CowenmainBuyBuy

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ginkgo.bio

News

Your note

Sign in to keep a note on DNA — it syncs with the Stock Master app.

Insider holders

DNA insider holders
InsiderRelationLatest transactionDateShares held
CANTON BARTHOLOMEWBeneficial Owner of more than 10% of a Class of SecuritySaleApr 9, 20260
COEN STEVEN P.Chief Financial OfficerSaleAug 23, 202651,851
DMYTRUK MARK EChief Financial OfficerSaleMay 20, 202546,226
HANNAN KATHY HOPINKAHDirectorConversion of Exercise of derivative securityJun 10, 202515,003
HENRY CHRISTIAN ODirectorSaleSep 14, 202619,310
KELLY JASON RChief Executive OfficerSaleApr 8, 2026316,483

Institution ownership

DNA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.73%4,282,90364.16MJun 29, 2026
Viking Global Investors, L.P.6.46%3,577,12853.59MJun 29, 2026
Erste Asset Management GmbH4.58%2,536,93938.00MJun 29, 2026
BAILLIE GIFFORD & CO4.32%2,391,64935.83MJun 29, 2026
Vanguard Capital Management LLC3.77%2,087,29331.27MJun 29, 2026
Anchorage Capital Group, LLC3.15%1,746,36326.16MJun 29, 2026

Fund ownership

DNA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.69%1,489,85122.32MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.23%1,232,83218.47MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.99%550,0718.24MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.94%523,1477.84MJul 30, 2026
PIMCO Equity Series-PIMCO RAE US Small Fund0.91%506,3127.58MJun 29, 2026
iShares Trust-iShares Russell 2000 Value ETF0.80%441,7786.62MAug 30, 2026